Boston Scientific (BSX) announced the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18. Smith currently serves as CFO of Starbucks (SBUX). Weber is the president and CEO of Takeda Pharmaceutical (TAK) since April 2015, retiring in June 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s TheraSphere Trial in Japan Signals New Growth Path in Liver Cancer
- Boston Scientific: BUY on WATCHMAN Growth Optionality and Favorable CHAMPION-AF Risk/Reward Setup
- Boston Scientific’s OPTION-EMEA Trial Targets One-Stop AF and Stroke Protection
- Boston Scientific: EP Market Growth Validated by Medtronic, Supporting Renewed Confidence in Buy Rating
- Boston Scientific price target lowered to $109 from $112 at Canaccord